Company Filing History:
Years Active: 2011
Title: The Innovations of Jill Reiter
Introduction
Jill Reiter is a prominent inventor based in New Haven, Connecticut. She has made significant contributions to the field of cancer research through her innovative patents. With a total of two patents to her name, her work focuses on the development of soluble epidermal growth factor receptor isoforms.
Latest Patents
Jill Reiter's latest patents include groundbreaking discoveries related to soluble isoforms of the Epidermal Growth Factor Receptor. The first patent details the discovery of soluble isoforms, or sErbB1 variants, and provides sequences of nucleic acids encoding these isoforms. It also discusses the use of immunoassay techniques to measure the concentration of these protein isoforms in patient biological samples. Furthermore, this invention offers methods for determining the presence of ovarian carcinoma by assaying the concentration of soluble ErbB1 variants. The second patent focuses on p110 soluble EGFR (p110 sEGFR) peptides and nucleic acid sequences. It includes antibodies, methods of detection, and kits for p110 sEGFR. This patent also outlines assays for evaluating cancer risk assessment, prevention, and early detection.
Career Highlights
Jill Reiter is currently associated with Tumor Biology Investment Group, Inc., where she continues her research and development efforts. Her work has been instrumental in advancing the understanding of cancer biomarkers and therapeutic methods.
Collaborations
Jill collaborates with notable colleagues, including Nita J Maihle and Andre T Baron, who contribute to her research initiatives.
Conclusion
Jill Reiter's innovative work in the field of cancer research exemplifies her dedication to improving diagnostic and therapeutic methods. Her patents reflect her commitment to advancing medical science and enhancing patient care.